300026 Stock Overview
Engages in the research, development, production, and marketing of various pharmaceutical products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Tianjin Chase Sun Pharmaceutical Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.98 |
| 52 Week High | CN¥4.87 |
| 52 Week Low | CN¥3.01 |
| Beta | -0.075 |
| 11 Month Change | -1.73% |
| 3 Month Change | 24.76% |
| 1 Year Change | -14.41% |
| 33 Year Change | -9.95% |
| 5 Year Change | 17.40% |
| Change since IPO | -34.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300026 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.2% | 0.3% | -0.6% |
| 1Y | -14.4% | -7.9% | 3.2% |
Return vs Industry: 300026 underperformed the CN Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: 300026 underperformed the CN Market which returned 3.2% over the past year.
Price Volatility
| 300026 volatility | |
|---|---|
| 300026 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300026 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300026's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 5,910 | Dan Zheng | www.chasesun.cn |
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China and internationally. The company offers Chinese medicine granules, finished pharmaceutical products, raw materials and excipients, medical devices, healthcare services, and smart supply chain for pharmaceutical and medical devices. It provides its products in the areas of severe disease, cardiovascular, cerebrovascular system, respiratory system, neurodegenerative, and anti-tumor.
Tianjin Chase Sun Pharmaceutical Co.,Ltd Fundamentals Summary
| 300026 fundamental statistics | |
|---|---|
| Market cap | CN¥11.96b |
| Earnings (TTM) | CN¥165.81m |
| Revenue (TTM) | CN¥5.63b |
72.1x
P/E Ratio2.1x
P/S RatioIs 300026 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300026 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.63b |
| Cost of Revenue | CN¥2.75b |
| Gross Profit | CN¥2.88b |
| Other Expenses | CN¥2.71b |
| Earnings | CN¥165.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.055 |
| Gross Margin | 51.12% |
| Net Profit Margin | 2.95% |
| Debt/Equity Ratio | 9.0% |
How did 300026 perform over the long term?
See historical performance and comparison